A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04895709

Public ClinicalTrials.gov record NCT04895709. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Study identification

NCT ID: NCT04895709
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 1,109 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 26, 2021
Primary completion: Aug 30, 2031
Completion: Aug 30, 2031
Last update posted: Aug 16, 2026

2021 – 2031

United States locations

U.S. sites: 11
U.S. states: 7
U.S. cities: 9

Facility	City	State	ZIP	Site status
Community Cancer Institute	Clovis	California	93611	Recruiting
USC/Norris Comprehensive Cancer Center	Los Angeles	California	90033	Recruiting
Hoag Memorial Hospital Presbyterian	Newport Beach	California	92663	Recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
John Theurer Cancer Center	Hackensack	New Jersey	07601	Recruiting
Local Institution - 0006	New York	New York	10032	Completed
Local Institution - 0002	New York	New York	10065	Completed
Providence Cancer Center Oncology and Hematology Care- Eastside	Portland	Oregon	97213	Recruiting
Local Institution - 0063	Nashville	Tennessee	37204	Withdrawn
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting
Houston Methodist Hospital	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04895709, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 16, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04895709 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →